Inveni, Omega invest €2.5m in BioSilta

The fresh capital will be used to pursue commercial expansion by bolstering BioSilta's sales and marketing teams in Europe and the US.

The company also plans on establishing distribution networks in other jurisdictions with the aim of increasing sales of its EnPresso product line.

Finally, the funding will allow BioSilta to begin developing a new pipeline of products.

Company
Founded in 2007, BioSilta is headquartered in Oulu with an office in Cambridge, UK. The company has developed its EnBase technology platform, designed to control the feeding – and therefore growth rate – of microbial cultures.

The platform allows for the development of reagent-based EnPresso growth systems. BioSilta claims its EnPresso product line increases protein yields by up to 100 times compared with using conventional growth methods of microbial cultures.

Its EnPresso products come in the form of pre-sterilised tablets, which are then added to sterile, filtered water.

People
Bob Penney is the CEO of BioSilta. Markku Fagerlund is a partner at Inveni, while Renée Aguiar-Lucander is a partner at Omega.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Nordics
• Healthcare
• Expansion
• Finland